Live webinar: Managing infection - a new paradigm

Tuesday, September 27
19:00 – 20:30
Hosted by Paul Chadwick
Clinical Director Royal College of Podiatry, UK
Register here

21 Apr 22
21 Apr 22
Biocomposites wins two Queen’s Awards for Enterprise in Innovation and International Trade
Innovation award recognises STIMULAN Rapid Cure as the only calcium sulfate antibiotic carrier approved for use in bone and soft tissue

International Trade award recognises Biocomposites’ outstanding continuous growth in overseas sales

Keele, UK, 21 April 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets…...
15 Jun 22
15 Jun 22
Biocomposites appoints Group Chief Financial Officer and New UK General Manager
Keele, UK, 15 June 2022 – Biocomposites, an international medical devices company that engineers, manufactures and…...
7 Dec 21
7 Dec 21
Biocomposites signs distribution agreement with NuVasive Specialized Orthopedics to supply STIMULAN® in Germany
STIMULAN® is the first and only calcium matrix approved as an antibiotic carrier for use in bone and soft tissue • Distribution established with leader in German orthopaedic market
Keele, UK, 7 December 2021 – Biocomposites, an international medical devices company that engineers, manufactures and…...
Pioneering calcium compounds

Innovation is at the very heart of what we do, resulting in over 100 grants and registrations.

Musculoskeletal infection

Growth of antibiotic-resistant biofilms continues to outpace the development of new antibiotics.

Dedicated to quality

Manufacturing, processing, testing and distribution are all handled in-house

Singular focus

Deep expertise and singular focus on calcium compound medical devices

Your specialty

Access case studies, clinical and pre-clinical papers for musculoskeletal infection, trauma and spine to see how we are innovating across a wide range of clinical applications to help surgeons and their patients.

Musculoskeletal infections

Musculoskeletal infections, including infected non-unions, osteomyelitis and periprosthetic joint infections, are one of the biggest healthcare challenges of the 21st century.

As the rapid growth of antibiotic-resistant strains and biofilms continues to outpace the development of new antibiotics and antibiotic strategies, care delivery is becoming increasingly challenging and complicated.


Bone and joint trauma, such as fractures and dislocations, are common and vary in severity from single fractures to multiple, life-threatening musculoskeletal injuries.

The most clinically challenging of these for the surgeon, and those that have the most socioeconomic burden, are open fractures. These often involve damage to the surrounding soft tissue, resulting in complications such as tissue and deep bone infection or long-term non-union.


The popularity of spine surgery differs around the world. The number of procedures performed in the USA is double the number performed in Western Europe, Canada and Australia combined, and five times the number in the UK.

In the USA, the number of spinal fusion procedures increased by 64% between 2002 and 2014, from approximately 268,000 to 414,000. The average cost per procedure has increased from $15,868 to $28,954 over the same period and was more than $12 billion in total in 2014.

Why Biocomposites?

At Biocomposites, we are pioneering calcium compound devices to regenerate and repair bone and soft tissue. With over 30 years’ experience of manipulating the surface chemistry and crystalline properties of calcium compounds, we engineer and manufacture products at the forefront of calcium technology.

  • Singular focus
  • Proprietary technology
  • Dedicated to quality
Learn more